Santhera and ReveraGen Submit NDA for Vamorolone in Duchenne Muscular Dystrophy
Swiss firm Santhera Pharmaceuticals and US-based ReveraGen BioPharma, Inc have announced the rolling submission of...
Company
Innovent’s Tyvyt Approved for New Gastric Cancer Indication by NMPA
China-based Innovent Biologics, Inc. (HKG: 1801) and its partner Eli Lilly & Co. (NYSE: LLY)...
Zhejiang Huahai Receives FDA ANDA Approval for Generic Tecfidera
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone
Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...
Salubris Partners with Alpha Molecular for AI-Driven Obesity Drug Development
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot...
RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022
China-based pharma firm RemeGen (HKG: 9995) released its Q3 2022 financial report, showing significant growth...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy
Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...
HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...
Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) released its Q3 2022 financial report, recording RMB 62.904...
Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...
Kintor Completes Enrollment for GT20029 Phase I Study in US
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...
Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial
Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...
WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan
China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...
Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...
CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...
Merck’s Q3 Sales Rise on Key Drug Performances, China Growth
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...
Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...